Der PE-konjugierte Maus Monoklonal anti-TCL1A Antikörper (Klon 1-21) (ABIN2663891) detektiert spezifisch TCL1A in FACS.
Dieser Antikörper reagiert spezifisch mit Proben aus Human.
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Protect from prolonged exposure to light. Do not freeze.
Lagerung
4 °C
Informationen zur Lagerung
The antibody solution should be stored undiluted between 2°C and 8°C.
Target
TCL1A
(T-Cell Leukemia/lymphoma 1A (TCL1A))
Andere Bezeichnung
TCL1
Hintergrund
TCL1, also known as T-cell leukemia/lymphoma protein 1A, protein p14 TCL1 and oncogene TCL-1, is a 14kD beta-barrel protein that was originally identified on the basis of its association with T-cell prolymphocytic leukemia (T-PLL). Activated by the T-cell receptor enhancer through inv(14)(q11,q32.1) or t(14,14)(q11,q32.1), TCL1 is normally expressed in immature cortical thymocytes, activated peripheral T-cells, pro-B cells, and naive mantle zone B cells of peripheral lymphoid tissues, but not in post-germinal center (GC) memory B cells and plasma cells. Akt and TCL1 interact via Akt's pleckstrin homology domain to form hetero-oligomers at the leaflet of the inner plasma membrane stimulating the protein kinase C-mitogen activated protein kinase-extracellular signal-related kinase (PKC-MAPK-ERK) signal transduction pathway. TCL1 also inhibits activation-induced cell death in T-cells by blocking PKCθ. In addition to T-PLL dysregulation is implicated in such B-cell neoplasias as lymphoblastic lymphoma, chronic lymphocytic leukemia (CLL) and Burkitt lymphoma.